About Vanta Bioscience
Vanta Bioscience is a publicly listed company based in Chennai (India) founded in 2010, and was acquired by Aragen in November 2014. GLP-certified preclinical contract research services are provided. The company has 43 employees. Its Indian entity Vanta Bioscience Limited reported revenue of ₹1.98 Cr. Vanta Bioscience offers products and services including Discovery Toxicology, Agro-chemicals and Chemical Safety, Biocompatibility Studies, Diet Formulation, and Batch Release Test. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified.
Company details
Vanta Bioscience was founded in 2010 in Chennai, India. Preclinical contract research services, certified under GLP standards, are offered to pharmaceutical, biotech, medical device, cosmetics, and chemical industries. Toxicology studies, biocompatibility assessments, and diet formulation services are included. A state-of-the-art research facility is maintained in compliance with international guidelines for animal care and use, with relevant accreditations ensuring adherence to regulatory requirements.
- Headquarters Chennai, India
- Employees 43
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website vantabio.com
- Social LinkedIn X
- Acquired by Aragen (Nov 2014)
- Legal Name Vanta Bioscience Ltd.
- Market Cap₹14.51 Cr
VANTABIO · BSE
- Share Price₹20.40
0.00% today
- Revenue₹1.82 Cr
FY 2025-26 · -7.1% YoY
- EBITDA₹1.02 Cr
Margin 56.0%
- Net Profit₹0.10 Cr
FY 2025-26 · +102.1% YoY
- P/E (TTM)134.0x
P/B 0.7x
- Investors
- Employee Count43
- Acquired byAragen
(Nov 2014)
Associated legal entities of Vanta Bioscience
Vanta Bioscience is associated with 2 registered companies on The Company Check; the primary company is Vanta Bioscience Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vanta Bioscience Limited Listed CIN L74999TG2016PLC109280 | Active | 29 Apr 2016 | Secunderabad, Telangana | ₹2.0 Cr | 43 | 8 | View details |
| Vanta Clinical Research Limited CIN U73100TG2018PLC126673 | Active | 12 Sep 2018 | Secunderabad, Telangana | ₹0.0 Cr | 3 | View details |
Products & Services of Vanta Bioscience
Vanta Bioscience offers a comprehensive portfolio of products and services, including Discovery Toxicology, Agro-chemicals and Chemical Safety, Biocompatibility Studies, Diet Formulation, and Batch Release Test.
Preclinical testing for drug safety and toxicity evaluation
Evaluation of safety for agrochemical products
Assessment of material compatibility for medical devices
Development of specialized diets for research studies
Testing for batch quality in pharmaceutical products
Investors in Vanta Bioscience
Vanta Bioscience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Aragen Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Aragen Life Sciences is engaged in contract research and manufacturing for pharmaceuticals. | 2001 | aragen.com | Hyderabad, India |
Investor details for Vanta Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Vanta Bioscience Limited (Vanta Bioscience)
Vanta Bioscience Limited is the primary company behind Vanta Bioscience. The boards of the 2 registered companies of Vanta Bioscience currently have 7 directors; the longest-serving is Dopesh Raja Mulakala, appointed in 2016. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Dopesh Raja Mulakala DIN 01176660 | Managing Director | 29 Apr 2016 | 10 yrs 5 mo | Vanta Bioscience Limited, Vanta Clinical Research Limited |
| Vyasmurti Madhavrao Shingatgeri DIN 07728757 | Whole-time director | 08 Feb 2017 | 9 yrs 8 mo | Vanta Bioscience Limited |
| Padmanabhuni Venkata Appaji DIN 02614167 | Director | 20 Mar 2017 | 9 yrs 7 mo | Vanta Bioscience Limited |
| Gonuguntla Kathyayani DIN 07824881 | Director | 19 May 2017 | 9 yrs 5 mo | Vanta Bioscience Limited |
| Yogeswara Rao Danda DIN 00694803 | Director | 22 May 2019 | 7 yrs 5 mo | Vanta Bioscience Limited |
| Mulakala Sajan Kiran DIN 00889262 | Director | 07 Mar 2020 | 6 yrs 7 mo | Vanta Clinical Research Limited |
| Shravan Chintapatla DIN 02698825 | Director | 18 Aug 2020 | 6 yrs 2 mo | Vanta Clinical Research Limited |
People of Vanta Bioscience
1 people are tracked at Vanta Bioscience (1 in leadership); the tracked headcount is 43.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Vanta Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vanta Bioscience
Vanta Bioscience is a publicly listed company on the BSE with ticker symbol VANTABIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Sep 2017
- Listed onBSE: 540729
- Listed entityVanta Bioscience Ltd.
- Exchange sectorHealth technology
- ISININE695X01011
- Share price₹20.42 · 2026-10-06
- Market capitalisation₹14.5 Cr
- Price to earnings134.1
- EPS (diluted, trailing year)₹0.15
- Volume (last session)2,250
Financials of Vanta Bioscience
Exchange-reported figures of Vanta Bioscience Limited, the listed company behind Vanta Bioscience (BSE: VANTABIO).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.82 | 1.96 | 9.72 | 6.28 | 9.69 | 10.04 | 14.14 |
| Revenue growth | -7.1% | -79.8% | +54.8% | -35.2% | -3.5% | -29.0% | - |
| EBITDA | 1.02 | (4.26) | 1.32 | (2.39) | 3.46 | 3.95 | 4.37 |
| EBITDA margin | +56.0% | -217.4% | +13.6% | -38.1% | +35.7% | +39.3% | +30.9% |
| Profit before tax | 0.01 | (12.64) | (8.82) | (10.26) | 0.21 | 0.59 | 1.34 |
| Net profit | 0.10 | (4.78) | (2.35) | (6.48) | 0.07 | 0.44 | 0.98 |
| Net profit margin | +5.5% | -243.9% | -24.2% | -103.2% | +0.7% | +4.4% | +6.9% |
| EPS (₹) | 0.15 | (7.56) | (3.67) | (10.27) | 0.14 | 0.71 | 1.59 |
| Balance sheet | |||||||
| Total assets | - | 73.87 | 73.93 | 76.09 | 74.21 | 62.20 | 41.83 |
| Net worth | - | 10.42 | 15.20 | 17.51 | 24.01 | 23.92 | 23.47 |
| Total debt | - | 70.09 | 60.96 | 57.16 | 44.86 | 35.97 | 17.37 |
| Cash & bank | - | 0.22 | 0.16 | 0.10 | 0.22 | 2.65 | 0.20 |
| Net working capital | - | 4.76 | 6.44 | 7.60 | 8.08 | 13.22 | 13.70 |
| Cash flow | |||||||
| Cash from operations | - | (2.41) | 2.68 | (0.63) | 5.28 | 6.97 | 2.34 |
| Cash from investing | - | (6.69) | (3.31) | (5.91) | (17.24) | (22.30) | (7.59) |
| Cash from financing | - | 9.16 | 0.69 | 6.41 | 9.53 | 17.78 | 2.17 |
| Particulars | Mar 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Revenue | 0.63 | 2.82 | 0.00 |
| Other income | 0.67 | 0.01 | 0.00 |
| EBITDA | (1.30) | (0.55) | 0.00 |
| EBITDA margin | -206.3% | -19.5% | - |
| Depreciation | 0.05 | 1.31 | 0.00 |
| Interest | 0.92 | 2.48 | 0.00 |
| Profit before tax | (1.36) | (2.47) | 0.38 |
| Tax | (0.01) | 0.09 | 0.38 |
| Net profit | (1.35) | (2.56) | 0.00 |
| EPS (₹) | 0.00 | (4.06) | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.82 | 1.13 | 8.56 | 5.17 | 9.35 | 10.04 | 14.11 |
| Revenue growth | +61.1% | -86.8% | +65.6% | -44.7% | -6.9% | -28.8% | - |
| EBITDA | 1.03 | (1.65) | 3.65 | (0.46) | 3.40 | 3.89 | 4.32 |
| EBITDA margin | +56.6% | -146.0% | +42.6% | -8.9% | +36.4% | +38.8% | +30.6% |
| Profit before tax | 0.02 | (2.71) | 0.04 | (4.19) | 0.14 | 0.60 | 1.29 |
| Net profit | 0.11 | (2.65) | 0.01 | (4.22) | 0.08 | 0.46 | 0.96 |
| Net profit margin | +6.0% | -234.5% | +0.1% | -81.6% | +0.9% | +4.6% | +6.8% |
| EPS (₹) | 0.17 | (4.21) | 0.08 | (6.71) | 0.12 | 0.75 | 1.55 |
| Balance sheet | |||||||
| Total assets | - | 47.60 | 45.17 | 45.50 | 44.76 | 41.19 | 37.59 |
| Net worth | - | 17.13 | 19.79 | 19.74 | 23.99 | 23.91 | 23.44 |
| Total debt | - | 30.47 | 25.38 | 25.76 | 20.77 | 17.28 | 14.15 |
| Cash & bank | - | 0.14 | 0.14 | 0.07 | 0.07 | 0.07 | 0.09 |
| Net working capital | - | 2.89 | 5.08 | 5.80 | 6.15 | 9.17 | 14.08 |
| Cash flow | |||||||
| Cash from operations | - | 1.36 | 4.55 | 0.64 | 6.70 | 11.01 | 3.17 |
| Cash from investing | - | (5.79) | (1.67) | (2.53) | (8.08) | (9.96) | (1.56) |
| Cash from financing | - | 4.43 | (2.81) | 1.88 | 1.38 | (1.07) | (1.80) |
| Particulars | Mar 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Revenue | 1.76 | 1.71 | 0.00 |
| Other income | 0.61 | 0.01 | 0.00 |
| Total expenses | 2.88 | 1.38 | 0.00 |
| EBITDA | (1.12) | 0.33 | 0.00 |
| EBITDA margin | -63.6% | +19.3% | - |
| Depreciation | 0.00 | 0.62 | 0.00 |
| Interest | 0.71 | 1.20 | 0.00 |
| Profit before tax | (1.22) | (1.48) | 0.00 |
| Tax | 0.00 | 0.01 | 0.00 |
Financial Statements
| Particulars | Mar 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Revenue | 0.63 | 2.82 | 0.00 |
| Other income | 0.67 | 0.01 | 0.00 |
| EBITDA | (1.30) | (0.55) | 0.00 |
| EBITDA margin | -206.3% | -19.5% | - |
| Depreciation | 0.05 | 1.31 | 0.00 |
| Interest | 0.92 | 2.48 | 0.00 |
| Profit before tax | (1.36) | (2.47) | 0.38 |
| Tax | (0.01) | 0.09 | 0.38 |
| Net profit | (1.35) | (2.56) | 0.00 |
| EPS (₹) | 0.00 | (4.06) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.82 | 1.96 | 9.72 | 6.28 | 9.69 | 10.04 | 14.14 |
| Revenue growth | -7.1% | -79.8% | +54.8% | -35.2% | -3.5% | -29.0% | - |
| Other income | 0.16 | 0.11 | 0.11 | 0.69 | 0.42 | 0.03 | 0.11 |
| Total expenses | 0.80 | 6.22 | 8.40 | 8.67 | 6.23 | 6.09 | 9.77 |
| Employee cost | 0.00 | 1.76 | 3.79 | 3.46 | 2.67 | 2.51 | 3.93 |
| EBITDA | 1.02 | (4.26) | 1.32 | (2.39) | 3.46 | 3.95 | 4.37 |
| EBITDA margin | +56.0% | -217.4% | +13.6% | -38.1% | +35.7% | +39.3% | +30.9% |
| Depreciation | 0.39 | 4.42 | 4.50 | 2.67 | 1.32 | 1.25 | 1.19 |
| Interest | 0.78 | 4.07 | 5.75 | 5.89 | 2.35 | 2.14 | 1.95 |
| Profit before tax | 0.01 | (12.64) | (8.82) | (10.26) | 0.21 | 0.59 | 1.34 |
| Tax | (0.09) | 0.66 | (0.22) | 0.18 | 0.09 | 0.14 | 0.33 |
| Net profit | 0.10 | (4.78) | (2.35) | (6.48) | 0.07 | 0.44 | 0.98 |
| Net profit margin | +5.5% | -243.9% | -24.2% | -103.2% | +0.7% | +4.4% | +6.9% |
| EPS (₹) | 0.15 | (7.56) | (3.67) | (10.27) | 0.14 | 0.71 | 1.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| Reserves & surplus | - | 4.11 | 8.89 | 11.20 | 17.70 | 17.61 | 17.16 |
| Shareholders' funds (net worth) | - | 10.42 | 15.20 | 17.51 | 24.01 | 23.92 | 23.47 |
| Minority interest | - | (6.64) | (2.23) | 1.41 | 5.34 | 2.31 | 0.99 |
| Secured loans | - | 29.18 | 34.64 | 45.28 | 36.83 | 30.37 | 16.27 |
| Unsecured loans | - | 40.91 | 26.32 | 11.88 | 8.03 | 5.60 | 1.10 |
| Total debt | - | 70.09 | 60.96 | 57.16 | 44.86 | 35.97 | 17.37 |
| Total liabilities | - | 73.87 | 73.93 | 76.09 | 74.21 | 62.20 | 41.83 |
| Assets | |||||||
| Gross block | - | 74.87 | 68.70 | 64.37 | 41.16 | 33.11 | 23.23 |
| Net block | - | 55.50 | 54.16 | 57.23 | 36.12 | 29.39 | 20.76 |
| Capital work in progress | - | 13.47 | 12.53 | 10.60 | 28.47 | 19.34 | 7.00 |
| Investments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | - | 6.51 | 7.52 | 7.16 | 7.24 | 9.76 | 14.01 |
| Sundry debtors | - | 2.50 | 3.14 | 1.96 | 1.13 | 2.01 | 1.39 |
| Cash & bank balances | - | 0.22 | 0.16 | 0.10 | 0.22 | 2.65 | 0.20 |
| Loans & advances | - | 6.13 | 6.34 | 6.03 | 5.90 | 5.51 | 4.25 |
| Total current assets | - | 15.36 | 17.16 | 15.25 | 14.49 | 19.93 | 19.85 |
| Total current liabilities | - | 10.60 | 10.72 | 7.65 | 6.41 | 6.71 | 6.15 |
| Net working capital | - | 4.76 | 6.44 | 7.60 | 8.08 | 13.22 | 13.70 |
| Total assets | - | 73.87 | 73.93 | 76.09 | 74.21 | 62.20 | 41.83 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.16 | 0.10 | 0.22 | 2.65 | 0.20 | 3.27 |
| Net cash from operating activities | - | (2.41) | 2.68 | (0.63) | 5.28 | 6.97 | 2.34 |
| Net cash from investing activities | - | (6.69) | (3.31) | (5.91) | (17.24) | (22.30) | (7.59) |
| Net cash from financing activities | - | 9.16 | 0.69 | 6.41 | 9.53 | 17.78 | 2.17 |
| Net change in cash | - | 0.06 | 0.06 | (0.13) | (2.43) | 2.46 | (3.07) |
| Closing cash | - | 0.22 | 0.16 | 0.10 | 0.22 | 2.65 | 0.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.1% | -79.8% | +54.8% | -35.2% | -3.5% | -29.0% | - |
| EBITDA growth | +123.9% | -422.7% | +155.2% | -169.1% | -12.4% | -9.6% | - |
| PBT growth | +9998.0% | -43.3% | +14.0% | - | -64.4% | -56.0% | +21.8% |
| Net income growth | +102.1% | -103.4% | +63.7% | -9357.1% | -84.1% | -55.1% | - |
| Revenue CAGR (3Y) | -33.8% | -41.3% | -1.1% | -23.7% | -7.9% | - | - |
| EBITDA CAGR (3Y) | - | - | -30.6% | - | +1.9% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +5.5% | -678.6% | -88.5% | -166.2% | +1.2% | +4.5% | +7.1% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | +4.0% | +5.4% | +8.6% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | +0.5% | +1.9% | +4.4% |
| Debt / equity | - | 5.11 | 3.61 | 2.46 | 1.69 | 1.13 | 0.67 |
| Long-term debt / equity | - | 4.02 | 2.93 | 2.05 | 1.46 | 1.00 | 0.63 |
| Interest cover | 123.81 | -46.89 | -180.82 | -116.40 | 109.81 | 79.26 | 61.32 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.03 | 0.15 | 0.12 | 0.26 | 0.36 | 0.67 |
| Inventory turnover | - | 0.28 | 1.32 | 0.87 | 1.14 | 0.84 | 1.22 |
| Debtors turnover | - | 0.70 | 3.81 | 4.06 | 6.17 | 5.91 | 9.59 |
| EPS (₹) | 0.15 | (7.56) | (3.67) | (10.27) | 0.14 | 0.71 | 1.59 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 16.51 | 24.08 | 27.75 | 38.03 | 37.89 | 37.18 |
| Particulars | Mar 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Revenue | 1.76 | 1.71 | 0.00 |
| Other income | 0.61 | 0.01 | 0.00 |
| Total expenses | 2.88 | 1.38 | 0.00 |
| EBITDA | (1.12) | 0.33 | 0.00 |
| EBITDA margin | -63.6% | +19.3% | - |
| Depreciation | 0.00 | 0.62 | 0.00 |
| Interest | 0.71 | 1.20 | 0.00 |
| Profit before tax | (1.22) | (1.48) | 0.00 |
| Tax | 0.00 | 0.01 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.82 | 1.13 | 8.56 | 5.17 | 9.35 | 10.04 | 14.11 |
| Revenue growth | +61.1% | -86.8% | +65.6% | -44.7% | -6.9% | -28.8% | - |
| Other income | 0.16 | 0.04 | 0.05 | 0.63 | 0.17 | 0.02 | 0.11 |
| Total expenses | 0.79 | 2.78 | 4.91 | 5.63 | 5.95 | 6.15 | 9.79 |
| Employee cost | 0.00 | 0.58 | 2.68 | 2.75 | 2.57 | 2.51 | 3.79 |
| EBITDA | 1.03 | (1.65) | 3.65 | (0.46) | 3.40 | 3.89 | 4.32 |
| EBITDA margin | +56.6% | -146.0% | +42.6% | -8.9% | +36.4% | +38.8% | +30.6% |
| Depreciation | 0.39 | 0.44 | 1.24 | 1.25 | 1.32 | 1.25 | 1.19 |
| Interest | 0.78 | 0.66 | 2.42 | 3.11 | 2.11 | 2.06 | 1.95 |
| Profit before tax | 0.02 | (2.71) | 0.04 | (4.19) | 0.14 | 0.60 | 1.29 |
| Tax | (0.09) | (0.06) | (0.01) | 0.03 | 0.06 | 0.13 | 0.31 |
| Net profit | 0.11 | (2.65) | 0.01 | (4.22) | 0.08 | 0.46 | 0.96 |
| Net profit margin | +6.0% | -234.5% | +0.1% | -81.6% | +0.9% | +4.6% | +6.8% |
| EPS (₹) | 0.17 | (4.21) | 0.08 | (6.71) | 0.12 | 0.75 | 1.55 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| Reserves & surplus | - | 10.82 | 13.48 | 13.43 | 17.68 | 17.60 | 17.13 |
| Shareholders' funds (net worth) | - | 17.13 | 19.79 | 19.74 | 23.99 | 23.91 | 23.44 |
| Secured loans | - | 15.06 | 16.83 | 18.24 | 17.29 | 16.68 | 13.55 |
| Unsecured loans | - | 15.41 | 8.55 | 7.52 | 3.48 | 0.60 | 0.60 |
| Total debt | - | 30.47 | 25.38 | 25.76 | 20.77 | 17.28 | 14.15 |
| Total liabilities | - | 47.60 | 45.17 | 45.50 | 44.76 | 41.19 | 37.59 |
| Assets | |||||||
| Gross block | - | 51.13 | 45.34 | 43.69 | 41.16 | 33.11 | 23.23 |
| Net block | - | 42.44 | 37.88 | 37.40 | 36.12 | 29.39 | 20.76 |
| Capital work in progress | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | - | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Inventories | - | 6.48 | 7.48 | 7.16 | 7.24 | 9.76 | 14.01 |
| Sundry debtors | - | 1.74 | 2.34 | 1.92 | 0.72 | 1.98 | 1.36 |
| Cash & bank balances | - | 0.14 | 0.14 | 0.07 | 0.07 | 0.07 | 0.09 |
| Loans & advances | - | 2.02 | 2.06 | 1.98 | 2.98 | 1.70 | 2.03 |
| Total current assets | - | 10.38 | 12.02 | 11.13 | 11.01 | 13.51 | 17.49 |
| Total current liabilities | - | 7.49 | 6.94 | 5.33 | 4.86 | 4.34 | 3.41 |
| Net working capital | - | 2.89 | 5.08 | 5.80 | 6.15 | 9.17 | 14.08 |
| Total assets | - | 47.60 | 45.17 | 45.50 | 44.76 | 41.19 | 37.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.14 | 0.07 | 0.07 | 0.07 | 0.09 | 0.28 |
| Net cash from operating activities | - | 1.36 | 4.55 | 0.64 | 6.70 | 11.01 | 3.17 |
| Net cash from investing activities | - | (5.79) | (1.67) | (2.53) | (8.08) | (9.96) | (1.56) |
| Net cash from financing activities | - | 4.43 | (2.81) | 1.88 | 1.38 | (1.07) | (1.80) |
| Net change in cash | - | 0.00 | 0.07 | 0.00 | 0.00 | (0.02) | (0.20) |
| Closing cash | - | 0.14 | 0.14 | 0.07 | 0.07 | 0.07 | 0.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +61.1% | -86.8% | +65.6% | -44.7% | -6.9% | -28.8% | - |
| EBITDA growth | +162.4% | -145.2% | +893.5% | -113.5% | -12.6% | -10.0% | - |
| PBT growth | +9998.0% | - | +9998.0% | - | -76.7% | -53.5% | +17.3% |
| Net income growth | +104.2% | - | +100.2% | -5375.0% | -82.6% | -52.1% | - |
| Revenue CAGR (3Y) | -29.4% | -50.6% | -5.2% | -28.4% | -9.0% | +36.0% | - |
| EBITDA CAGR (3Y) | - | - | -2.1% | - | +1.3% | +55.7% | - |
| Profitability & leverage | |||||||
| Net income margin | +6.0% | -234.5% | +0.6% | -81.6% | +0.9% | +4.7% | +7.0% |
| Return on capital employed | - | 0.0% | +5.2% | 0.0% | +5.2% | +6.8% | +8.9% |
| Return on net worth | - | 0.0% | +0.1% | 0.0% | +0.3% | +2.0% | +4.3% |
| Debt / equity | - | 1.51 | 1.29 | 1.06 | 0.79 | 0.66 | 0.60 |
| Long-term debt / equity | - | 1.02 | 0.99 | 0.83 | 0.55 | 0.49 | 0.56 |
| Interest cover | 121.88 | -31.58 | 100.41 | -181.87 | 101.44 | 78.03 | 62.30 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.02 | 0.19 | 0.12 | 0.25 | 0.36 | 0.67 |
| Inventory turnover | - | 0.16 | 1.17 | 0.72 | 1.10 | 0.84 | 1.21 |
| Debtors turnover | - | 0.55 | 4.02 | 3.92 | 6.93 | 6.01 | 9.66 |
| EPS (₹) | 0.17 | (4.21) | 0.08 | (6.71) | 0.12 | 0.75 | 1.55 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 27.14 | 31.36 | 31.28 | 38.01 | 37.88 | 37.14 |
Timeline of Vanta Bioscience
3 dated milestones of Vanta Bioscience across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Vanta Bioscience is founded.
- Exit Acquired by Aragen.
- IPO Lists on the stock exchange (IPO).
Web traffic of Vanta Bioscience
The website of Vanta Bioscience (vantabio.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 26.8% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Vanta Bioscience (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vanta Bioscience
Complete news archive for Vanta Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vanta Bioscience
Vanta Bioscience was founded in 2010.
Vanta Bioscience is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Vanta Bioscience has 43 employees.
The primary company behind Vanta Bioscience, Vanta Bioscience Limited, reported revenue of ₹1.98 Cr for FY 2026, down 7% year on year.
Vanta Bioscience was founded in 2010 in Chennai, India. Preclinical contract research services, certified under GLP standards, are offered to pharmaceutical, biotech, medical device, cosmetics, and chemical industries. Toxicology studies, biocompatibility assessments, and diet formulation services are included. A state-of-the-art research facility is maintained in compliance with international guidelines for animal care and use, with relevant accreditations ensuring adherence to regulatory requirements.
Vanta Bioscience offers Discovery Toxicology, Agro-chemicals and Chemical Safety, Biocompatibility Studies, Diet Formulation, and Batch Release Test.
Yes, Vanta Bioscience is publicly traded on BSE under the ticker symbol VANTABIO.
Vanta Bioscience has 1 investor. Key investors include Aragen Life Sciences.
Vanta Bioscience is associated with 2 legal entities: Vanta Bioscience Limited, Vanta Clinical Research Limited.
Yes. Vanta Bioscience was acquired by Aragen in November 2014.
The legal entities of Vanta Bioscience currently have 10 directors, including Dopesh Raja Mulakala, Vyasmurti Madhavrao Shingatgeri, Venkata Sathya Murali Dokka and others.